Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTPW) Depreciation and Depletion (2022 - 2025)

Historic Depreciation and Depletion for 60 Degrees Pharmaceuticals (SXTPW) over the last 4 years, with Q3 2025 value amounting to $12225.0.

  • 60 Degrees Pharmaceuticals' Depreciation and Depletion rose 18207.2% to $12225.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $33604.0, marking a year-over-year increase of 31221.79%. This contributed to the annual value of $11726.0 for FY2024, which is 4458.94% down from last year.
  • Per 60 Degrees Pharmaceuticals' latest filing, its Depreciation and Depletion stood at $12225.0 for Q3 2025, which was up 18207.2% from $9236.0 recorded in Q2 2025.
  • In the past 5 years, 60 Degrees Pharmaceuticals' Depreciation and Depletion ranged from a high of $12225.0 in Q3 2025 and a low of $407.0 during Q1 2024
  • Over the past 4 years, 60 Degrees Pharmaceuticals' median Depreciation and Depletion value was $6797.5 (recorded in 2022), while the average stood at $5839.0.
  • Per our database at Business Quant, 60 Degrees Pharmaceuticals' Depreciation and Depletion crashed by 9410.23% in 2024 and then soared by 154471.74% in 2025.
  • 60 Degrees Pharmaceuticals' Depreciation and Depletion (Quarter) stood at $6901.0 in 2022, then crashed by 72.83% to $1875.0 in 2023, then soared by 190.61% to $5449.0 in 2024, then surged by 124.35% to $12225.0 in 2025.
  • Its Depreciation and Depletion stands at $12225.0 for Q3 2025, versus $9236.0 for Q2 2025 and $6694.0 for Q1 2025.